Low- and middle-income countries are set to be more adversely impacted by trial terminations and suspensions due to the funding pull from the US Agency for International Development (USAID), a researcher has said.
Funding to USAID has been paused for 85 days, but there is a risk that funding will not return. The funding pull has meant several clinical trials have been stopped in their tracks. This has raised ethical concerns in the industry about how patients will be monitored and provided with healthcare as part of the trials if funding does not return.
Go deeper with GlobalData
Research funded by USAID includes trials for therapies to tackle human immunodeficiency virus (HIV), tuberculosis and malaria. These diseases heavily impact populations in low- and middle-income countries, which rely on public funding to fund research efforts.
The Clinical Trials Arena team spoke to Professor Anna Roca, Professor of Epidemiology at the London School of Hygiene and Tropical Medicine’s Medical Research Council (MRC) Unit the Gambia, and Research Professor for the Catalan Institution for Research and Advanced Studies (ICREA) at ISGlobal, the Barcelona Institute for Global Health, who said that low- and middle-income countries will bear the brunt of the funding pull.
You can listen to the podcast here:
